Friday, 16 October 2026European Markets

AKER HORIZONS Stock Bullish Momentum With A 24% Jump In The Last 10 Sessions

Loading stream...

(VIANEWS) - Shares of AKER HORIZONS (Oslo Børs Benchmark Index_GI: AKH.OL) rose by a staggering 24.82% in 10 sessions from kr7.05 to kr8.80 at 17:23 EST on Monday, after three consecutive sessions in a row of gains. Oslo Børs Benchmark Index_GI is falling 0.39% to kr1,220.66, following the last session's upward trend.

About AKER HORIZONS

Aker Horizons ASA, through its subsidiaries, develops and invests in a portfolio of companies in the renewable energy and green technology comprising private and public companies worldwide. It sources, develops, structures, builds, and operates wind and solar power assets; and develops, builds, owns, and operates clean hydrogen production at industrial scale. The company also provides products, technology, and solutions within the field of carbon capture, utilization, and storage. In addition, it offers products and services to the hydropower industry; designs and delivers superconducting systems; and produces silicon materials. The company was incorporated in 2020 and is headquartered in Lysaker, Norway. Aker Horizons ASA is a subsidiary of Aker Capital AS.

Earnings Per Share

As for profitability, AKER HORIZONS has a trailing twelve months EPS of kr-4.82.

Volume

Today's last reported volume for AKER HORIZONS is 999835 which is 48.09% below its average volume of 1354480.

Volatility

AKER HORIZONS's last week, last month's, and last quarter's current intraday variation average was 3.95%, 0.47%, and 3.41%.

AKER HORIZONS's highest amplitude of average volatility was 3.95% (last week), 4.44% (last month), and 3.41% (last quarter).

More news about AKER HORIZONS (AKH.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com